Sab biotherapeutics rebrands as sab bio

New name, logo and website updates, stock symbol will remain sabs with new brand identity, sab bio continues drive towards serious unmet needs in type 1 diabetes miami, june 20, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced its new name, sab bio, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform. this rebrand includes a new name, logo mark and website updates to reflect the company's strategic evolution.
SABS Ratings Summary
SABS Quant Ranking